Penumbra, Inc. (PEN) fundamentals: P/E, valuation, undervalued?
Penumbra, Inc. · Health Care · ref. ETF XLV · price $321
In short — Penumbra, Inc. trades at 79.5× earnings (P/E), 52.3× forward, with a net margin of 10.7 % and revenue growth of +15 %. Read: Very expensive vs its growth (P/E 52 very high vs ~15% growth (PEG 3.5)).
Is Penumbra, Inc. stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$321+18.2% over range
Aug 28, 25low $225.54 · high $359.4Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 3 analysts
Valuation : Very expensive vs its growth — P/E 52 very high vs ~15% growth (PEG 3.5)
Valuation
79.5
P/E (price/earnings)
52.3
Forward P/E
—
PEG
8.3
Price/book (P/B)
$12.6B
Market cap
4.04
EPS
Profitability & growth
10.7 %
Net margin
+15 %
Revenue growth
-24 %
Earnings growth
$213M
Total debt
Penumbra, Inc. income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $847M | $-2M | -0.2 % |
| 2023 | $1.1B | $91M | 8.6 % |
| 2024 | $1.2B | $14M | 1.2 % |
| 2025 | $1.4B | $178M | 12.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Penumbra, Inc.'s P/E and is the stock undervalued? What's a good P/E?
Penumbra, Inc.'s P/E is 79.5 (forward 52.3). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Very expensive vs its growth".
Is Penumbra, Inc. profitable?
Penumbra, Inc. has a net margin of 10.7 % (EPS 4.04). The company is profitable.
Is PEN stock expensive?
Our read: "Very expensive vs its growth" — P/E 52 very high vs ~15% growth (PEG 3.5). Cross-check with growth and sector.
💬 A question about Penumbra, Inc.? The JPI assistant answers using our backtest data.
Keep exploring Penumbra, Inc.